Jining First People's Hospital, Jining Medical University, Jining, China.
Department of Mental Health, Jining Medical University, Jining, China.
Free Radic Biol Med. 2018 Dec;129:440-445. doi: 10.1016/j.freeradbiomed.2018.10.418. Epub 2018 Oct 15.
Doxorubicin (Dox) is an effective anti-cancer agent, whose clinical use is limited by the cytotoxicity in non-target tissues, especially the heart and brain. The drug-induced neuronal damage is primarily mediated by oxidative stress, in which autophagy plays a central role. Although numerous studies indicate the involvement of autophagy in neurodegenerative diseases and brain injury, the evidence concerning autophagic process in Dox-induced neuronal death is limited. We found that repeated Dox administration induced the protein expression of LC3II and P62 and impaired autophagic flux with enhanced autophagasome accumulation in rat hippocampus, whereas two weeks after the cessation of Dox treatment, the autophagic process was restored, even stimulated, with normalized protein levels of LC3II and P62 and enhanced expression of Becline-1, indicating a compensatory response in the recovery state. Likewise, while repeated Dox exposure inhibited the hippocampal expression of lysosomal-associated membrane protein 2 (LAMP2) and cathepsin D (CTSD), and suppressed CTSD activity, the Dox-induced impaired autophagy-lysosome pathway was also restored in rats following two weeks of recovery. To further verify the role of autophagy, the autophagy inhibitor, 3-methyladenine (3-MA), was administrated daily for the two weeks of recovery period. Our data demonstrated that while the animals in the recovery state showed a significant trend to decreased oxidative damage, normalized antioxidative system and ameliorated endoplasmic reticulum (ER) stress compared with Dox-induced toxic model, 3-MA treatment abrogated the recovering process, resulting in sustained oxidative and ER stress and neuronal apoptosis. Collectively, the present study firstly provided the evidence for the involvement of autophagy in both development and recovery of Dox-induced neurotoxicity, highlighting a novel target for mitigating the chemotherapy-induced neuronal damage.
多柔比星(Dox)是一种有效的抗癌药物,但由于其在非靶组织中的细胞毒性,尤其是在心脏和大脑中的细胞毒性,限制了其临床应用。该药物引起的神经元损伤主要是由氧化应激介导的,自噬在其中发挥核心作用。尽管许多研究表明自噬参与神经退行性疾病和脑损伤,但关于多柔比星诱导的神经元死亡中自噬过程的证据有限。我们发现,重复给予多柔比星可诱导 LC3II 和 P62 的蛋白表达,并损害自噬流,导致自噬小体在大鼠海马中的积累增加,而在停止多柔比星治疗两周后,自噬过程被恢复,甚至被刺激,LC3II 和 P62 的蛋白水平正常化,Becline-1 的表达增强,表明在恢复状态下存在代偿反应。同样,虽然重复暴露于多柔比星可抑制海马体溶酶体相关膜蛋白 2(LAMP2)和组织蛋白酶 D(CTSD)的表达,并抑制 CTSD 活性,但在两周的恢复后,多柔比星诱导的受损自噬-溶酶体途径也在大鼠中得到恢复。为了进一步验证自噬的作用,给予自噬抑制剂 3-甲基腺嘌呤(3-MA),每日一次,持续两周的恢复时间。我们的数据表明,在恢复状态下的动物与多柔比星诱导的毒性模型相比,氧化损伤减少、抗氧化系统正常化以及内质网(ER)应激减轻呈显著趋势,而 3-MA 治疗则破坏了恢复过程,导致持续的氧化和 ER 应激以及神经元凋亡。总的来说,本研究首次提供了自噬参与多柔比星诱导的神经毒性发生和恢复的证据,为减轻化疗引起的神经元损伤提供了一个新的靶点。